請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41546
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江伯倫(Bor-Luen Chiang) | |
dc.contributor.author | Wen-Hsin Tsai | en |
dc.contributor.author | 蔡文心 | zh_TW |
dc.date.accessioned | 2021-06-15T00:22:33Z | - |
dc.date.available | 2009-08-02 | |
dc.date.copyright | 2009-02-17 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-02-03 | |
dc.identifier.citation | 1. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 2000 May;47(5):670-9.
2. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999 Oct;23(2):185-8. 3. Archer HL, Whatley SD, Evans JC, Ravine D, Huppke P, Kerr A, et al. Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet 2006 May;43(5):451-6. 4. Ariani F, Mari F, Pescucci C, Longo I, Bruttini M, Meloni I, et al. Real-time quantitative PCR as a routine method for screening large rearrangements in Rett syndrome: Report of one case of MECP2 deletion and one case of MECP2 duplication. Hum Mutat 2004 Aug;24(2):172-7. 5. Armstrong J, Pineda M, Aibar E, Gean E, Monros E. Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation. Ann Neurol 2001 Nov;50(5):692. 6. Budden SS. Rett syndrome: habilitation and management reviewed. Eur Child Adolesc Psychiatry 1997;6 Suppl 1:103-7. 7. Burford B. Perturbations in the development of infants with Rett disorder and the implications for early diagnosis. Brain Dev 2005 Nov;27 Suppl 1:S3-S7. 8. Bzduch V, Zahorakova D, Grechanina E, Zdibskaja EP, Goldfarb IG, Zeman J, et al. A case of Rett syndrome from Ukraine--clinical diagnosis confirmed by mutation analysis of the MECP2 gene. Bratisl Lek Listy 2004;105(9):299-302. 9. Chae JH, Hwang H, Hwang YS, Cheong HJ, Kim KJ. Influence of MECP2 gene mutation and X-chromosome inactivation on the Rett syndrome phenotype. J Child Neurol 2004 Jul;19(7):503-8. 10. Charman T, Neilson TC, Mash V, Archer H, Gardiner MT, Knudsen GP, et al. Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype-phenotype associations in Rett syndrome. Eur J Hum Genet 2005 Oct;13(10):1121-30. 11. Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard H, et al. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet 2000 Apr 12;9(7):1119-29. 12. Clayton-Smith J, Watson P, Ramsden S, Black GC. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 2000 Sep 2;356(9232):830-2. 13. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet 2004 Nov 1;13(21):2679-89. 14. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, et al. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 2001 Apr 15;10(9):941-6. 15. del Gaudio D, Fang P, Scaglia F, Ward PA, Craigen WJ, Glaze DG, et al. Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet Med 2006 Dec;8(12):784-92. 16. Dotti MT, Orrico A, De Stefano N, Battisti C, Sicurelli F, Severi S, et al. A Rett syndrome MECP2 mutation that causes mental retardation in men. Neurology 2002 Jan 22;58(2):226-30. 17. Einspieler C, Kerr AM, Prechtl HF. Is the early development of girls with Rett disorder really normal? Pediatr Res 2005 May;57(5 Pt 1):696-700. 18. Erlandson A, Samuelsson L, Hagberg B, Kyllerman M, Vujic M, Wahlstrom J. Multiplex ligation-dependent probe amplification (MLPA) detects large deletions in the MECP2 gene of Swedish Rett syndrome patients. Genet Test 2003 Winter;7(4):329-32. 19. Evans JC, Archer HL, Colley JP, Ravn K, Nielsen JB, Kerr A, et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet 2005 Oct;13(10):1113-20. 20. Friez MJ, Jones JR, Clarkson K, Lubs H, Abuelo D, Bier JA, et al. Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics 2006 Dec;118(6):e1687-95. 21. Geerdink N, Rotteveel JJ, Lammens M, Sistermans EA, Heikens GT, Gabreels FJ, et al. MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings. Neuropediatrics 2002 Feb;33(1):33-6. 22. Glaze DG. Neurophysiology of Rett syndrome. J Child Neurol 2005 Sep;20(9):740-6. 23. Glaze DG, Schultz RJ, Frost JD. Rett syndrome: characterization of seizures versus non-seizures. Electroencephalogr Clin Neurophysiol 1998 Jan;106(1):79-83. 24. Gomot M, Gendrot C, Verloes A, Raynaud M, David A, Yntema HG, et al. MECP2 gene mutations in non-syndromic X-linked mental retardation: phenotype-genotype correlation. Am J Med Genet A 2003 Dec 1;123A(2):129-39. 25. Hagberg B, Gillberg C. . Rett variants+/-rettoid phenotypes. Rett Syndrome:Clinical and Biological Aspects. Hagberg B, Anvret M, Wahlstrom J, editor. London: MacKeith Press; 1993. 26. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol 2002;6(5):293-7. 27. Hagberg B, Witt-Engerstrom I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. Am J Med Genet Suppl 1986;1:47-59. 28. Hagberg BA. Rett syndrome: clinical peculiarities, diagnostic approach, and possible cause. Pediatr Neurol 1989 Mar-Apr;5(2):75-83. 29. Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001 Jun 12;56(11):1486-95. 30. Huppke P, Gartner J. Molecular diagnosis of Rett syndrome. J Child Neurol 2005 Sep;20(9):732-6. 31. Huppke P, Held M, Hanefeld F, Engel W, Laccone F. Influence of mutation type and location on phenotype in 123 patients with Rett syndrome. Neuropediatrics 2002 Apr;33(2):63-8. 32. Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet 2000 May 22;9(9):1369-75. 33. Imessaoudene B, Bonnefont JP, Royer G, Cormier-Daire V, Lyonnet S, Lyon G, et al. MECP2 mutation in non-fatal, non-progressive encephalopathy in a male. J Med Genet 2001 Mar;38(3):171-4. 34. Kammoun F, de Roux N, Boespflug-Tanguy O, Vallee L, Seng R, Tardieu M, et al. Screening of MECP2 coding sequence in patients with phenotypes of decreasing likelihood for Rett syndrome: a cohort of 171 cases. J Med Genet 2004 Jun;41(6):e85. 35. Kankirawatana P, Leonard H, Ellaway C, Scurlock J, Mansour A, Makris CM, et al. Early progressive encephalopathy in boys and MECP2 mutations. Neurology 2006 Jul 11;67(1):164-6. 36. Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A. A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. Am J Hum Genet 2002 Apr;70(4):1034-7. 37. Kleefstra T, Yntema HG, Nillesen WM, Oudakker AR, Mullaart RA, Geerdink N, et al. MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics. Eur J Hum Genet 2004 Jan;12(1):24-8. 38. Laccone F, Huppke P, Hanefeld F, Meins M. Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions. Hum Mutat 2001 Mar;17(3):183-90. 39. Laccone F, Junemann I, Whatley S, Morgan R, Butler R, Huppke P, et al. Large deletions of the MECP2 gene detected by gene dosage analysis in patients with Rett syndrome. Hum Mutat 2004 Mar;23(3):234-44. 40. Laccone F, Zoll B, Huppke P, Hanefeld F, Pepinski W, Trappe R. MECP2 gene nucleotide changes and their pathogenicity in males: proceed with caution. J Med Genet 2002 Aug;39(8):586-8. 41. Li MR, Pan H, Bao XH, Zhang YZ, Wu XR. MECP2 and CDKL5 gene mutation analysis in Chinese patients with Rett syndrome. J Hum Genet 2007;52(1):38-47. 42. Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A, et al. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet 2008 Nov 5. 43. Masuyama T, Matsuo M, Jing JJ, Tabara Y, Kitsuki K, Yamagata H, et al. Classic Rett syndrome in a boy with R133C mutation of MECP2. Brain Dev 2005 Sep;27(6):439-42. 44. Meins M, Lehmann J, Gerresheim F, Herchenbach J, Hagedorn M, Hameister K, et al. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J Med Genet 2005 Feb;42(2):e12. 45. Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D'Adamo P, et al. A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 2000 Oct;67(4):982-5. 46. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 2004 Apr;36(4):339-41. 47. Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, Schoonbrood-Lenssen AM, et al. Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2). Eur J Paediatr Neurol 2003;7(1):5-12. 48. Motil KJ, Schultz RJ, Wong WW, Glaze DG. Increased energy expenditure associated with repetitive involuntary movement does not contribute to growth failure in girls with Rett syndrome. J Pediatr 1998 Feb;132(2):228-33. 49. Nicolao P, Carella M, Giometto B, Tavolato B, Cattin R, Giovannucci-Uzielli ML, et al. DHPLC analysis of the MECP2 gene in Italian Rett patients. Hum Mutat 2001 Aug;18(2):132-40. 50. Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, et al. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 2000 Sep 22;481(3):285-8. 51. Percy AK, Lane JB. Rett syndrome: model of neurodevelopmental disorders. J Child Neurol 2005 Sep;20(9):718-21. 52. Philippe C, Villard L, De Roux N, Raynaud M, Bonnefond JP, Pasquier L, et al. Spectrum and distribution of MECP2 mutations in 424 Rett syndrome patients: a molecular update. Eur J Med Genet 2006 Jan-Feb;49(1):9-18. 53. Quenard A, Yilmaz S, Fontaine H, Bienvenu T, Moncla A, des Portes V, et al. Deleterious mutations in exon 1 of MECP2 in Rett syndrome. Eur J Med Genet 2006 Jul-Aug;49(4):313-22. 54. Ravn K, Nielsen JB, Skjeldal OH, Kerr A, Hulten M, Schwartz M. Large genomic rearrangements in MECP2. Hum Mutat 2005 Mar;25(3):324. 55. Scala E, Ariani F, Mari F, Caselli R, Pescucci C, Longo I, et al. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J Med Genet 2005 Feb;42(2):103-7. 56. Schanen C, Francke U. A severely affected male born into a Rett syndrome kindred supports X-linked inheritance and allows extension of the exclusion map. Am J Hum Genet 1998 Jul;63(1):267-9. 57. Schanen C, Houwink EJ, Dorrani N, Lane J, Everett R, Feng A, et al. Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. Am J Med Genet A 2004 Apr 15;126A(2):129-40. 58. Schanen NC, Kurczynski TW, Brunelle D, Woodcock MM, Dure LSt, Percy AK. Neonatal encephalopathy in two boys in families with recurrent Rett syndrome. J Child Neurol 1998 May;13(5):229-31. 59. Schollen E, Smeets E, Deflem E, Fryns JP, Matthijs G. Gross rearrangements in the MECP2 gene in three patients with Rett syndrome: implications for routine diagnosis of Rett syndrome. Hum Mutat 2003 Aug;22(2):116-20. 60. Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. Neuropediatrics 2001 Jun;32(3):162-4. 61. Shi J, Shibayama A, Liu Q, Nguyen VQ, Feng J, Santos M, et al. Detection of heterozygous deletions and duplications in the MECP2 gene in Rett syndrome by Robust Dosage PCR (RD-PCR). Hum Mutat 2005 May;25(5):505. 62. Smeets E, Schollen E, Moog U, Matthijs G, Herbergs J, Smeets H, et al. Rett syndrome in adolescent and adult females: clinical and molecular genetic findings. Am J Med Genet A 2003 Oct 15;122A(3):227-33. 63. Smeets E, Terhal P, Casaer P, Peters A, Midro A, Schollen E, et al. Rett syndrome in females with CTS hot spot deletions: a disorder profile. Am J Med Genet A 2005 Jan 15;132A(2):117-20. 64. Smyk M, Obersztyn E, Nowakowska B, Nawara M, Cheung SW, Mazurczak T, et al. Different-sized duplications of Xq28, including MECP2, in three males with mental retardation, absent or delayed speech, and recurrent infections. Am J Med Genet B Neuropsychiatr Genet 2008 Sep 5;147B(6):799-806. 65. Steffenburg U, Hagberg G, Hagberg B. Epilepsy in a representative series of Rett syndrome. Acta Paediatr 2001 Jan;90(1):34-9. 66. Tao J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M, et al. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet 2004 Dec;75(6):1149-54. 67. Topcu M, Akyerli C, Sayi A, Toruner GA, Kocoglu SR, Cimbis M, et al. Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. Eur J Hum Genet 2002 Jan;10(1):77-81. 68. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 2005 Sep;77(3):442-53. 69. Villard L. MECP2 mutations in males. J Med Genet 2007 Jul;44(7):417-23. 70. Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, Fontes M. Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 2000 Oct 24;55(8):1188-93. 71. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 1999 Dec;65(6):1520-9. 72. Watson P, Black G, Ramsden S, Barrow M, Super M, Kerr B, et al. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J Med Genet 2001 Apr;38(4):224-8. 73. Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 2004 Dec;75(6):1079-93. 74. Witt Engerstrom I. Age-related occurrence of signs and symptoms in the Rett syndrome. Brain Dev 1992 May;14 Suppl:S11-20. 75. Ylisaukko-Oja T, Rehnstrom K, Vanhala R, Kempas E, von Koskull H, Tengstrom C, et al. MECP2 mutation analysis in patients with mental retardation. Am J Med Genet A 2005 Jan 15;132A(2):121-4. 76. Yntema HG, Kleefstra T, Oudakker AR, Romein T, de Vries BB, Nillesen W, et al. Low frequency of MECP2 mutations in mentally retarded males. Eur J Hum Genet 2002 Aug;10(8):487-90. 77. Zappella M, Gillberg C, Ehlers S. The preserved speech variant: a subgroup of the Rett complex: a clinical report of 30 cases. J Autism Dev Disord 1998 Dec;28(6):519-26. 78. Zeev BB, Yaron Y, Schanen NC, Wolf H, Brandt N, Ginot N, et al. Rett syndrome: clinical manifestations in males with MECP2 mutations. J Child Neurol 2002 Jan;17(1):20-4. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41546 | - |
dc.description.abstract | 一、研究目的:台灣地區典型或非典型蕾特氏症候群患者的基因診斷率向來偏低。我們首先藉由臨床診斷分群,再運用兩階段的篩檢方式,先進行MECP2基因編碼區直接定序,再加上MLPA(Multiplex Ligation-dependent Probe Amplification)的方式進行大片斷缺失突變分析,期能提高台灣地區有關蕾特氏症候群的基因突變篩檢率。我們針對大台北地區典型或非典型蕾特氏症候群以及類蕾特氏症候群患兒轉介至台大醫院做MECP2基因突變篩檢者,分析其MECP2基因突變的結果。我們希望建立台灣本土關於典型或非典型蕾特氏症候群或類蕾特氏症候群患兒MECP2基因突變型的資料庫。
二、研究背景:蕾特氏症候群是一種罕見的進行性神經系統退化及發展遲緩的疾病,通常好發於小女孩。蕾特氏症候群罹患率約1/10,000-15,000女孩左右。西元1999年蕾特氏症的致病基因被發現是位於染色體Xq28的MECP2基因突變所導致。若男性發生突變,則會死產或在出生後兩年內死亡。約有80∼90%的典型蕾特氏症候群患兒在MECP2基因的編碼區(coding region)發生點突變,然而剩下的10∼20%的患兒可能屬於基因的缺失突變,突變在其他基因的部分,或基因尚未確定。一些研究結果顯示有一部份MECP2基因的編碼區沒有點突變的病人,事實上有大片段的缺失突變。因此,我們決定使用兩階段的篩檢方式,除了直接定序外再加上MLPA進行MECP2基因大片斷缺失突變分析,期能提高台灣地區關於蕾特氏症候群患者MECP2基因突變的檢出率。 三、研究方法:我們收集自2003年12月至2008年11月期間由大台北地區各級醫院因臨床症狀疑似典型、非典型、或類蕾特氏症候群患兒而轉介至台大醫院來做MECP2基因突變分析的個案。研究個案依據Hagberg et al於西元2002發表的典型蕾特氏症候群診斷標準修改版,以及變異型蕾特氏症候群診斷標準來分類。若符合典型或非典型蕾特氏症候群診斷或類蕾特氏症候群患兒,則直接做MECP2基因直接定序來偵測其中基因編碼區是否存在突變。而未檢出突變者,再利用MLPA來偵測是否存在大片段的缺失突變。另一群病人未能符合典型或非典型蕾特氏症候群診斷標準,則歸類於未明原因身心發展遲緩患者。我們假設當中部分個案有可能疑似MECP2基因相關疾病患者,因此藉由MECP2-MLPA的試驗去探討此族群中偵測出MECP2雙倍數(duplication)突變的可能性。 四、研究結果:總共收案97位,其中有23符合典型蕾特氏症候群,37位為非典型或類蕾特氏症候群;其他有37位為歸類為未明原因身心發展遲緩疑似MECP2基因相關疾病患者。在23符合典型蕾特氏症候群族群中突變偵測率為60.1% (14/23)。在非典型或類蕾特氏症候群患者中突變偵測率為8.1% (3/37)。在37位未明原因身心發展遲緩個案中,我們找到1位有涵蓋MECP2基因的雙倍數突變,突變偵測率佔男性未明原因智障的4.0% (1/25)。我們總共從17個符合典型或非典型蕾特氏症候群患者的個案找到14種不同的突變,1種unclassified variant or mutation。14種不同的突變中,11個是點突變,3個是缺失突變。大部分的突變是missense mutations ,佔57.1% (8/14),其次是nonsense mutations,佔21.4% (3/14)以及frame shift mutations,佔21.4% (3/14)。 14種不同的突變當中有5種突變是本研究的新發現。其一是nonsense mutation,是C>T 的取代發生在cDNA 844 (c.844C>T),造成TGA (stop codon) 取代CGA (arginine) (p.R282X);另外三個是missense mutation (p.S149Y, p.V207M, p.Q437H);以及一個是有83個鹼基在exon4發生缺失突變(c.1117_1199del83)造成frameshift(p.S373fs)。另外有一個文獻中有報導過被歸類為unclassified variant or mutations的突變點(p.R344W),也在本研究中一位其臨床表現為典型蕾特氏症候群的女孩找到。此外,我們由MLPA篩檢找到台灣首例MECP2基因雙倍數突變的男性患者。 五、結論: 在台灣大部份針對MECP2基因突變的篩檢是PCR-based以及只侷限在基因的編碼區,因此很大的可能會遺漏掉此基因的大片段缺失突變。據我們了解,在台灣地區我們的研究是第一個用MLPA的方式去針對蕾特氏症候群及類蕾特氏症候群患兒進行MECP2基因的突變分析,也是第一個研究用MLPA的方式去找出MECP2雙倍數突變是造成男性智能障礙的可能原因之一。雖然,我們並未如預期地在蕾特氏症候群及類蕾特氏症候群患兒身上找到MECP2基因的大片段缺失突變,我們相信用MLPA的方式去針對定序結果陰性的蕾特氏症候群患者做進一步的篩檢,仍是非常重要的工作。 | zh_TW |
dc.description.abstract | Background: Mutations in the methy-CpG-binding protein 2 (MECP2) gene are well known to cause Rett syndrome (RTT), a severe neurodevelopmental disorder, occurs almost exclusively in females, with an estimated prevalence of approximately 1 in 10,000-15,000 females. RTT is often considered an X-linked dominant condition with male lethality (Hagberg 1985) characterized by a progressive loss of intellectual function, fine gross motor skills, and communicative abilities; deceleration of head growth; and the development of stereotypic hand movements, all occurring after a period of normal development. To date, mutations have been identified in the MECP2 sequences of approximately 80-90% of all RTT; the remaining 10-20% may possess noncoding regions of this gene, or they may harbor a second RTT inducing gene or locus. Several reports have identified large gene deletions in RTT patients that escaped detection by PCR-based screening strategies (Laccone et al. 2004; Schollen et al. 2003).
This study reports the result of the mutation analysis of MECP2 in 97 patients with classic or atypical RTT or RTT-like, conducted to obtain a genotypeic representation of the mutational spectrum in Taipei, Taiwan. Patients and Methods: A total of 97 clinically suspicious RTT or RTT-like patients, referred to National Taiwan University Hospital for MECP2 gene mutation analysis, were involved in this study. Patients were grouping according to the clinical diagnostic criteria for the classic or variant Rett syndrome proposed by The Rett Syndrome Diagnostic Criteria Work Group (Hagberg et al. 2002), consisting of 23 classic, 37 atypical or RTT-like, and 37 grouped into idiopathic psychomotor retardation patients.The first group composed of RTT or RTT-like patients who were fulfilled the diagnostic criteria, and this group underwent DNA direct sequencing. In the mutation-negative patient, we used multiplex ligation-dependent probe amplification (MLPA) kit P015C to screen for large deletions. The other group who weren’t fulfill the classic or atypical RTT diagnostic criteria, were considered as idiopathic psychomotor retardation, but who may be related to the MECP2-related disorders were underwent MECP2-MLPA test directly to study the possible role of MECP2 duplication in this group. Results: Mutations in MECP2 were detected in 60.1% (14/23) of the patients presenting with classic RTT, and in 8.1% (3/37) of those with atypical RTT or RTT-like features. In total, 14 different MECP2 mutations, and 1 unclassified variant or mutation were identified in 17 of the 60 diagnosed as classical or atypical RTT or RTT-like patients. Most of the variants were missense mutations, accounting for 57.1% (8/14), followed by nonsense mutations 21.4% (3/14), and frame shift mutations 21.4% (3/14). We identified five novel mutations, four of which were point mutations, and one was deletion. The first, a nonsense mutation, C>T transition at the cDNA 844 (c.844C>T), lead to CGA change to TGA and became a stop codon (p.R282X). The other three were missense mutations (p.S149Y, p.V207M, p.Q437H), and one was a 83bp deletion (c.1117_1199del83) happened in exon 4 and lead to frameshift (p.S373fs). No mutations were found in exon 1 or 2 based on our study. However, we did not pinpoint a significant relationship between genotype and phenotype in these cases. In the group of 37 patients with idiopathic psychomotor retardation, we identified one case with Xq28 duplication including MECP2 gene. Conclusion: In Taiwan, most of the screenings are PCR-based and restricted to the coding part of the gene and therefore prone to miss gene dosage changes. To our knowledge, this is the first study in Taiwan to determine the role of large deletions of the MECP2 in RTT or RTT-like patients using MLPA method. Also, it is the first study in Taiwan to determine the possible role of duplications of the MECP2 region in children with psychomotor retardation using MLPA method. Although there was no large deletion of MECP2 found in our patients with Rett or Rett-like syndrome, it remains important to screen large deletions in these patients. Because duplication of MECP2 gene remains one of the possibilities in patients with psychomotor retardation of unknown etiology, we recommend screening MECP2 gene duplications in males with moderate to severe developmental delay, especially when a history of recurrent infections has been documented. We will continue our work to screen the large deletion of MECP2 gene in RTT or RTT-like patients, and the duplication of MECP2 gene in children with psychomotor retardation of unknown etiology to clarify the role of such changes in these patients. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T00:22:33Z (GMT). No. of bitstreams: 1 ntu-98-P94421027-1.pdf: 1012901 bytes, checksum: ffc0a034f8402cc2c79662ccbbc0fd4e (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 封面 i
口試委員會審定書 ii 誌謝 iii 目錄 viii 圖目錄 x 表目錄 xi 第1章 緒論 1 1.1 研究背景與文獻探討 1 1.1.1 蕾特氏症候群簡介 1 1.1.2 MECP2基因以及相關疾病 2 1.1.3 蕾特氏症候群的診斷方式: 5 1.1.4 MECP2基因的分子檢測方式及其應用 6 1.1.5 基因型與表線型之關連(Genotype-Phenotype Correlations) 11 1.1.6 鑑別診斷(Differential Diagnosis) 12 1.2 欲研究的問題及其重要性 13 1.3 研究假說 15 1.4 研究目的 15 第2章 研究方法與材料 16 2.1 個案收集(Patients) 16 2.1.1 診斷策略(Diagnostic Strategies)(圖 1)16 2.2 實驗方式(Methods) 17 2.2.1 方法一 17 2.2.2 方法二 17 2.2.3 方法三 18 第3章 研究結果 19 3.1 第一部份 19 3.2 第二部分 用MLPA的方式偵測到的MECP2基因突變 22 3.2.1 實驗結果 22 3.2.2 關於有MECP2 雙倍數複製突變個案的臨床特徵 22 第4章 討論 24 4.1 討論第一節MEPC2基因的突變分析 24 4.2 討論第二節MECP2 duplication syndrome 29 第5章 展望 30 第6章 論文英文簡述(Summary) 34 參考文獻 44 附圖 52 附表 58 | |
dc.language.iso | zh-TW | |
dc.title | 對蕾特氏症候群及類蕾特氏症候群患兒進行臨床以及MECP2基因的突變分析 | zh_TW |
dc.title | Mutation Analysis of the MECP2 Gene in Patients with Rett Syndrome and Rett-like Features | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 李旺祚(Wang-Tso Lee) | |
dc.contributor.oralexamcommittee | 洪焜隆,蘇怡寧,張開屏 | |
dc.subject.keyword | 蕾特氏症候群,MECP2基因,MLPA,突變分析, | zh_TW |
dc.subject.keyword | Rett syndrome,MECP2,MLPA,Mutation analysis, | en |
dc.relation.page | 63 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-02-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 989.16 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。